Advertisement: TTP Killer 50
12 December, 2013 - 11:15 By News Desk

MISSION Therapeutics

mission therapeutics, deubiquitylating enzymes, cancer, cambridge

Founded in 2011, the company raised $86.37m in fresh money early in 2016 – taking its funding haul to date past the $125m mark. Woodford Patient Capital Trust became a new investor.

The company focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. 

The latest round enabled MISSION to maximise the potential of its world leading DUB platform and advance a series of first-in-class small molecule drugs candidates targeting specific DUBs into clinical development.

Newsletter Subscription

Stay informed of the latest news and features